Evidence map›Paper›PMID 39459977›Full record

ArticleViruses2024

Benchmarking of an Intervention Aiming at the Micro-Elimination of Hepatitis C in Vulnerable Populations in Perpignan, France, to Inform Scale-Up and Elimination on the French Territory.

Gordana Avramovic, Laura O'Doherty, Tina McHugh, Andre Jean Remy, Arnaud Happiette, Hakim Bouchkira, Philippe Murat, Olivier Scemama, Adrien Esclade, Maria Isabel Farfan Camacho and 2 more

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. The SCANVIRViruses · 2026
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gordana AvramovicMater Misericordiae University Hospital, 44 Eccles St, D07 R2WY Dublin, Ireland.ORCID 0000-0001-9610-6472
Laura O'DohertyMater Misericordiae University Hospital, 44 Eccles St, D07 R2WY Dublin, Ireland.
Tina McHughMater Misericordiae University Hospital, 44 Eccles St, D07 R2WY Dublin, Ireland.
Andre Jean RemyCentre Hospitalier de Perpignan-20 Avenue du Languedoc, 66046 Perpignam, France.ORCID 0000-0001-5067-1417
Arnaud HappietteCentre Hospitalier de Perpignan-20 Avenue du Languedoc, 66046 Perpignam, France.
Hakim BouchkiraCentre Hospitalier de Perpignan-20 Avenue du Languedoc, 66046 Perpignam, France.
Philippe MuratMinistère de la Santé et de la Prévention, 14, Avenue Duquesne, 75007 Paris, France.
Olivier ScemamaMinistère de la Santé et de la Prévention, 14, Avenue Duquesne, 75007 Paris, France.
Adrien EscladeMinistère de la Santé et de la Prévention, 14, Avenue Duquesne, 75007 Paris, France.
Maria Isabel Farfan CamachoEuropean Commission, Directorate-General for Structural Reform Support, CHARL 9/100, B-1049 Brussels, Belgium.
Walter CullenCatherine McAuley Centre, University College Dublin, 21 Nelson St, D07 A8NN Dublin, Ireland.
John S LambertMater Misericordiae University Hospital, 44 Eccles St, D07 R2WY Dublin, Ireland.

Funding

Directorate General for Reform Support, European Union SRSS/S2019/068
6 · The paper itself

Abstract

Hepatitis C virus (HCV) is an important cause of chronic liver disease. Among at-risk populations, access to care is challenging. The French Ministry of Health has supported a seek-and-treat pilot intervention aiming at micro-elimination in Perpignan, France, to inform scale-up of elimination efforts across the whole territory. University College Dublin (UCD) led a successful EU funded project, called HepCare, focusing on the micro-elimination of HCV. UCD was contracted to evaluate and benchmark the Perpignan results against results from HepCare. Using mixed-method approaches including qualitative interviews with patients, a focus group with healthcare professionals, and quantitative analyses of the cascade of care against results obtained at other European sites, we analyse the acceptability, reproducibility, replicability, and effectiveness of the Perpignan intervention. A total of 960 participants were recruited in the Perpignan area. HCV antibody test results were obtained for 928 (96.6%), of which 150 (15.6%) were antibody-positive. Of the antibody-positive participants, 68 (45.3%) tested positive for HCV-RNA, 141 (94%) were linked to care, and of the HCV-RNA-positive participants, 60 (88%) started treatment. Of those who underwent treatment, 34 (56.7%) completed treatment and achieved a sustained viral response (SVR) at dataset closure, 18 (30%) were still in treatment, 5 (8.3%) defaulted from treatment, and 3 (5%) had a virologic failure or died. The intervention in Perpignan was acceptable to patients, but had limitations in effectiveness, as shown in comparisons with HepCare results. To engage harder-to-reach cohorts in France, future models of care in the territory should incorporate peer support.

Indexed as

BenchmarkingHepacivirusHepatitis CVulnerable PopulationsAdultAgedAntiviral AgentsDisease EradicationFemaleFranceHepatitis C, ChronicHumansMaleMiddle AgedYoung AdultAntiviral AgentsbenchmarkHCV eliminationhepatitis Cintegrated carepeople who inject drugsPWIDsystems of carevulnerable populations

Identifiers

PMID39459977
PMCPMC11512308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.